AGIO agios.com Net earnings per share for the last 12 months

Public company logo of Agios Pharmaceuticals (AGIO)

This chart, where the current level is -6.27, confirms the financial resilience of Agios Pharmaceuticals (AGIO) driven by oncology royalties and liquid reserves. The rolling annual earnings per share value is based on the firm's leadership in pyruvate kinase deficiency therapy for orphan patients. Meanwhile, the moderate predictability of cash flows depends directly on the development of new drugs and market competition.

AGIO (Agios Corp) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/15/2026

Analytical breakdowns and data insights for company Agios Corp (AGIO)

- stock price and consensus target price:
Fundamental company valuation:Agios (AGIO)
Mass-produced product of Agios Pharmaceuticals Inc

This metric reflects the rolling annual net income per share, allowing for an assessment of business capitalization efficiency and its ability to generate real income. For Agios Pharmaceuticals (AGIO), which possesses a monopoly platform for rare disease therapy, the 12-month net income per share chart demonstrates the financial results of a lack of market alternatives and resilient demand.

Competitors of Agios Pharmaceuticals

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|GPCR: Net earnings per share (EPS TTM)|MDXG - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Rezolute Bio|Lexicon Corp (LXRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months mbxbio.com (MBX)|Net earnings per share (EPS TTM) altimmune.com (ALT)|Net earnings per share (EPS TTM) AARD (aardvarktherapeutics.com)|Net earnings per share for the last four quarters Sagimet Biosciences Inc. (SGMT)|BioAge Labs, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Biomea Fusion Corp BMEA|QNCX: Net earnings per share (EPS TTM)|Fractyl Health, Inc. (GUTS) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months VTVT|Agape ATP Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PLUR|SYBX - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) LPCN (lipocine.com)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS